Summit Therapeutics (SMMT) Change in Cash (2019 - 2026)

Summit Therapeutics' Change in Cash history runs 8 years deep, the most recent figure standing at -$118.8 million for Q1 2026.

• Quarterly Change in Cash fell 211.34% year-over-year to -$118.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$105.0 million (down 169.9% YoY) and the FY2025 annual result came in at $120.4 million, up 256.6% from the prior year.
• Change in Cash was -$118.8 million for Q1 2026 at Summit Therapeutics, down from -$13.3 million in the prior quarter.
• Across five years, Change in Cash topped out at $526.6 million in Q4 2022 and bottomed at -$577.6 million in Q1 2023.
• A 5-year average of $2.1 million and a median of -$9.8 million in 2024 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash jumped 6327.22% — and 2023, when it sank 10307.42%.
• Summit Therapeutics' Change in Cash stood at $526.6 million in 2022, then plunged by 90.96% to $47.6 million in 2023, then tumbled by 76.72% to $11.1 million in 2024, then sank by 219.88% to -$13.3 million in 2025, then plunged by 793.33% to -$118.8 million in 2026.
• Business Quant data shows SMMT's Change in Cash at -$118.8 million in Q1 2026, -$13.3 million in Q4 2025, and -$59.3 million in Q3 2025.